Quick-Med and Avery Dennison Enter into Joint Development Agreement

Quick-Med Technologies, Inc. (OTCBB: QMDT) and Avery Dennison Corporation (NYSE: AVY) announced today that they entered into a joint development and exclusive option agreement to collaborate in applying Quick-Med’s proprietary NIMBUS^® technology to adhesives for medical device and industrial applications.

"We are excited to team with Avery Dennison Corporation to incorporate our advanced NIMBUS technology in adhesives,” said J. Ladd Greeno, CEO of Quick-Med Technologies. "Avery Dennison is the respected leader in developing advanced adhesives to meet the requirements of medical device manufacturers. This collaboration will leverage NIMBUS technology to a next generation of antimicrobial adhesives to address growing infection concerns.”

"Our partnership with Quick-Med will enable us to bring innovative, next-generation antimicrobial technology to meet the needs of both existing and potential customers,” said Kevin Young, Vice President & General Manager of Avery Dennison Corporation. "NIMBUS technology will continue Avery Dennison innovation firsts by bringing much needed, uniquely effective and affordable, non-leaching antimicrobial protection to applications for the medical devices market.”

What makes NIMBUS different from other antimicrobial technology is its permanent bond and its ability to be effective even in the presence of large amounts of serum and body fluids. The active agent is permanently bonded to the substrate, keeping the biocide from depletion or leaching antimicrobials into the wound, while killing microbes (such as MRSA, VRE, and many others) that are present on the device. Being bound to the substrate keeps the antimicrobial at full strength; test results show that even in 90% serum, NIMBUS continues to kill microbes outperforming other antimicrobials.

About NIMBUS^®

NIMBUS is a next-generation antimicrobial technology that is non-leaching, non-toxic, long-lasting and not blocked by organics such as blood, urine and perspiration. According to Gregory Schultz, Professor, Institute for Wound Research at the University of Florida and Past President of the Wound Healing Society, "NIMBUS poses no danger of bacteria developing resistance, or of releasing toxic material into the wound and impeding the wound healing process. It is a novel technology: bonded and effective even in high concentrations of body fluids.”

About Avery Dennison Corporation

Avery Dennison is a recognized industry leader that develops innovative identification and decorative solutions for businesses and consumers worldwide. The Company’s products include pressure-sensitive labeling materials; graphics imaging media; retail apparel ticketing and branding systems; RFID inlays and tags; office products; specialty tapes; and a variety of specialized labels for automotive, industrial and durable goods applications. A FORTUNE 500 Company with sales of $6.7 billion in 2008, Avery Dennison is based in Pasadena, California and employs more than 36,000 employees in over 60 countries. For more information, visit www.averydennison.com.

About Quick-Med Technologies, Inc.

Quick-Med Technologies, Inc. is a life sciences company that is developing innovative technologies for the healthcare and consumer markets. For more information, see: www.quickmedtech.com.

© 2009 Quick-Med Technologies, Inc. All rights reserved. NIMBUS^® is a registered trademark of Quick-Med Technologies, Inc.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "expect," "plan," "believe," "anticipate," "intend," "could," "would," "estimate," and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at www.sec.gov.